Vera Therapeutics, Inc. Net Income Loss

• Vera Therapeutics, Inc. showed a decrease of -96.9% in Net Income Loss from 2024 to 2025.
• This data is from Vera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Vera Therapeutics, Inc.'s Net Income Loss has declined by 460.9%.
• Historical annual values: Fiscal year 2025: -$299.62 million | Fiscal year 2024: -$152.15 million | Fiscal year 2023: -$95.99 million | Fiscal year 2022: -$89.06 million | Fiscal year 2021: -$32.61 million | Fiscal year 2020: -$53.41 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026